Streetbeat News

EIGR

Eiger BioPharmaceuticals Inc

http://www.eigerbio.com/

CEO

David Cory

Employees

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

eiger inc is a research company located in 500 crescent ct ste 300, dallas, texas, united states.

Open

1.90

Mkt cap

2.6M

Volume

130K

High

1.90

P/E Ratio

-0.03

52-wk high

43.35

Low

1.73

Div yield

N/A

52-wk low

1.10

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has filed for Chapter 11 bankruptcy protection and announced a 'stalking horse' agreement to sell Zokinvy to Sentynl Therapeutics for up to $26M. The sale is subject to court approval and other potential bids. Eiger aims to sell most of its assets and wind down operations smoothly, ensuring uninterrupted access to Zokinvy for patients.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 3:16 pm

U.S. stocks showed mixed performance with the Dow Jones dropping over 200 points, while the NASDAQ rose. The S&P 500 slightly fell. The ISM manufacturing PMI increased to 50.3 in March, surpassing expectations. MediaCo Holding, Meta Materials, and Doma Holdings saw significant stock price increases, while Eiger BioPharmaceuticals, AEON Biopharma, and Logistic Properties Of The Americas experienced notable declines.

Portfolio Pulse from Avi Kapoor

April 01, 2024 | 2:39 pm

Health care stocks showed significant movement in Thursday's intraday session, with notable gainers including Yield10 Bioscience, Monogram Orthopaedics, and X4 Pharmaceuticals, among others. Losers were led by Tourmaline Bio, Apyx Medical, and Ontrak. The movements were largely influenced by recent Q4 earnings reports.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 5:31 pm

Eiger BioPharmaceuticals and its partner AnGes have received approval in Japan for Zokinvy (lonafarnib) to treat Hutchinson-Gilford Progeria Syndrome and related conditions. Eiger will receive a $500K milestone payment as a result of this approval.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 10:52 pm

Trading for EIGR was halted and then resumed at 8:55 AM ET, with an update on news and resumption times provided.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:55 pm

Trading on Eiger BioPharmaceuticals, Inc. (EIGR) was halted at 7:50:00 p.m. ET due to pending news. The halt is in place to ensure a fair and orderly market until the pending news is released to the public.

Portfolio Pulse from Benzinga Newsdesk

January 06, 2024 | 12:50 am

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) announced a 1-for-30 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. The split will be effective on January 5, 2024, with post-split trading starting on January 8, 2024. The split was approved by stockholders and the Board on December 28, 2023, and will reduce outstanding shares from 44.4 million to approximately 1.5 million. Adjustments will be made to outstanding equity awards and the number of shares issuable under equity incentive plans.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:32 pm

In Wednesday's after-market session, several healthcare stocks experienced significant movements. Atara Biotherapeutics (ATRA) saw a 24.3% increase, while MoonLake (MLTX) rose by 12.98%. TC BioPharm (TCBP), Perspective Therapeutics (CATX), Lucy Scientific Discovery (LSDI), and Calliditas Therapeutics (CALT) also posted gains. Conversely, Jin Medical International (ZJYL) led the losers with a 10.7% decline, followed by Avalo Therapeutics (AVTX), Eiger BioPharmaceuticals (EIGR), Monogram Orthopaedics (MGRM), LogicMark (LGMK), and Aclarion (ACON) with notable decreases.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 9:31 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Avidity Biosciences (RNA) led the gainers with a 38.1% increase, while Tharimmune (THAR) saw the largest drop among the losers, falling 69.5%. Other notable movers included Heart Test Laboratories (HSCS), Redhill Biopharma (RDHL), icad (ICAD), and Eiger BioPharmaceuticals (EIGR) with substantial gains, and SenesTech (SNES), CohBar (CWBR), Nexalin Technology (NXL), Better Therapeutics (BTTX), and Altamira Therapeutics (CYTO) with notable losses.

Portfolio Pulse from Benzinga Insights

November 28, 2023 | 1:06 pm

Moshe Arkin has reported a 10.09% stake in Eiger Biopharmaceuticals and sent a letter to the board suggesting that the company should file a New Drug Application (NDA) for Lonafarnib, a potential treatment in their pipeline.

Portfolio Pulse from Charles Gross

November 24, 2023 | 11:16 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.